Medications not intended for treatment of dyslipidemias and with a variable effect on lipids.

abstract：:Nitric oxide is a ubiquitous molecule involved in a variety of biological processes. The specific action of NO depends on its enzymatic sources namely neuronal nitric oxide synthase (nNOS), endothelial NOS (eNOS) and inducible NOS (iNOS) and all three isoforms have been localized in the gastrointestinal tract. Constit...

journal_title：Current pharmaceutical design

authors： Barrachina MD,Panés J,Esplugues JV

更新日期：2001-01-01 00:00:00

abstract：:Although somewhat controversial, there is good evidence that long-distance travel in general is a risk factor for venous thromboembolism, even in the absence of other risk factors. This is probably due to effects consequent to prolonged sitting but air travel in particular may be associated with risk factors other tha...

journal_title：Current pharmaceutical design

authors： Bradford A

更新日期：2007-01-01 00:00:00

abstract：:Today, in spite of being older than a century (born in 1911), the Pictet-Spengler two component reaction (PS-2CR) is still one of the most popular reactions, not only for the synthesis of tetrahydroisoquinolines (THIQs), tetrahydro-β-carbolines (THBCs), or more complex structures containing these two privileged moieti...

journal_title：Current pharmaceutical design

authors： Ingallina C,D'Acquarica I,Delle Monache G,Ghirga F,Quaglio D,Ghirga P,Berardozzi S,Markovic V,Botta B

更新日期：2016-01-01 00:00:00

abstract：:Angiotensin-converting enzyme (ACE) inhibitors represent one of the most commonly used categories of drugs in canine and feline medicine. ACE inhibitors currently approved for use in veterinary medicine are benazepril, enalapril, imidapril and ramipril. They are all pro-drugs administered by oral route. A physiologica...

journal_title：Current pharmaceutical design

authors： Lefebvre HP,Brown SA,Chetboul V,King JN,Pouchelon JL,Toutain PL

更新日期：2007-01-01 00:00:00

abstract：:Backgound: Current drug therapy for the management of arterial hypertension and heart failure has provided substantial benefits but has also some limitations. LCZ696, a dual inhibitor of angiotensin receptor blockers and neprilysin, and finerenone, a non-steroidal mineralocorticoid receptor antagonist, are two recentl...

journal_title：Current pharmaceutical design

authors： Faselis C,Boutari C,Doumas M,Imprialos K,Stavropoulos K,Kokkinos P

更新日期：2017-01-01 00:00:00

abstract：:Aspirin is the cornerstone of treatment in patients with coronary artery disease. However, several studies investigating the in vitro response of platelets to the administration of aspirin showed this response to be variable, with some patients exhibiting non-responsiveness or resistance. Aspirin resistance may be cat...

journal_title：Current pharmaceutical design

authors： Papathanasiou A,Goudevenos J,Tselepis AD

更新日期：2009-01-01 00:00:00

abstract：BACKGROUND:Discovery and development of BCS class 1 drugs through high throughput screening is one of the biggest challenge faced by formulation scientist. METHODS:There are a number of approaches that have been exploited to enhance the solubility and permeability of drugs. Among them, development of nanosuspension ha...

journal_title：Current pharmaceutical design

authors： Arora D,Khurana B,Rath G,Nanda S,Goyal AK

更新日期：2018-01-01 00:00:00

abstract：:Colchicine is a lipophilic alkaloid drug, which exhibits ant-inflammatory and anti-fibrotic properties. Cardinal mechanisms of action of colchicine are the disruption of the microtubule system and the inhibition of neutrophil adhesion and recruitment. Colchicine is indicated in the prevention and treatment of gouty ar...

journal_title：Current pharmaceutical design

authors： Marinaki S,Skalioti C,Boletis JN

更新日期：2018-01-01 00:00:00

abstract：:Natural products have served humankind as drug leads for thousands of years. In the last century natural products have not only served as drugs but have inspired the generation of countless synthetic drugs and drug-leads around natural product pharmacophores. There are no disease targets for which natural products hav...

journal_title：Current pharmaceutical design

authors： Hamann MT

更新日期：2007-01-01 00:00:00

abstract：:The clinical presentation of heart disease is different between men and women and this distinction is pivotal for a correct diagnosis and an adequate treatment. However, the definition of symptoms classically associated with heart disease is mainly based on the characteristics of those reported in men. Chest pain or c...

journal_title：Current pharmaceutical design

authors： Collins P,Vitale C,Spoletini I,Barbaro G

更新日期：2011-01-01 00:00:00

abstract：:Glucocorticoids are the first line medication used in the therapy of many severe inflammatory disorders. They exert their activity through binding to the glucocorticoid receptor, a ligand-dependent transcription factor, and result in either activation or repression of a large set of glucocorticoid responsive genes. Th...

journal_title：Current pharmaceutical design

authors： Schulz M,Eggert M

更新日期：2004-01-01 00:00:00

abstract：:Over the last decade, much was learned about the biology of several types of stem and progenitor cells. It has become apparent that various cell sources may have the capacity to promote cardiomyogenesis and new blood vessel formation through different mechanisms, forming the rationale for cell-based therapy in patient...

journal_title：Current pharmaceutical design

authors： Rodrigo SF,Ramshorst Jv,Beeres SL,Bax JJ,Schalij MJ,Atsma DE

更新日期：2011-10-01 00:00:00

abstract：BACKGROUND:Cardiac resynchronization therapy (CRT) is a valuable intracardiac device--based treatment option for a subgroup of patients with advanced heart failure (HF) and QRS prolongation. However, still a significant proportion of patients do not benefit from CRT implantation, labeled as non-responders. OBJECTIVES:...

journal_title：Current pharmaceutical design

authors： Debska-Kozlowska A,Ksiazczyk M,Warchol I,Lubinski A

更新日期：2019-01-01 00:00:00

abstract：:Fibrates are widely prescribed lipid-lowering drug in the treatment of dyslipidemia. Their main clinical effects, mediated by peroxisome proliferative activated receptor (PPAR) alpha activation, are a moderate reduction in total cholesterol and low-density lipoprotein cholesterol (LDL-C) levels, a marked reduction in ...

journal_title：Current pharmaceutical design

authors： Ansquer JC,Foucher C,Aubonnet P,Le Malicot K

更新日期：2009-01-01 00:00:00

abstract：:Angiogenic eye disease is among the most common causes of blindness worldwide. Current treatment approaches are insufficiently effective and partially associated with significant adverse effects. From an investigational view, the eye provides an ideal setting to observe real-time and serial observations of angiogenesi...

journal_title：Current pharmaceutical design

authors： Wegewitz U,Göhring I,Spranger J

更新日期：2005-01-01 00:00:00

abstract：BACKGROUND:Vaginal infections caused by non-albicans species have become common in women of all age groups. The resistance of species such as Candida parapsilosis to the various antifungal agents is a risk factor attributed to these types of infections, which instigates the search for new sources of active compounds in...

journal_title：Current pharmaceutical design

authors： C de Lima L,A S Ramos M,Toledo LG,Rodero CF,Hilário F,Dos Santos LC,Chorilli M,Bauab TM

更新日期：2020-01-01 00:00:00

abstract：:In this review we discuss the role of protonation states in receptor-ligand interactions, providing experimental evidences and computational predictions that complex formation may involve titratable groups with unusual pKa's and that protonation states frequently change from unbound to bound states. These protonation ...

journal_title：Current pharmaceutical design

authors： Petukh M,Stefl S,Alexov E

更新日期：2013-01-01 00:00:00

abstract：:The three opioid receptors, mu, delta and kappa all mediate analgesia, and knockout mice with opioid receptor deletion have proven unique tools to investigate in vivo opioid pharmacology. Since a few years, a number of new mouse lines have been engineered, with several distinct mutations of the mu receptor, to assess ...

journal_title：Current pharmaceutical design

authors： Gavériaux-Ruff C

更新日期：2013-01-01 00:00:00

abstract：:Providing novel treatments to help cancer patients live longer and have better lives remains one of the biggest challenges of the pharmaceutical industry. Today much is known about the molecular and genetic causes of cancers thus facilitating the development of novel targeted cancer drugs with improved risk-benefit ra...

journal_title：Current pharmaceutical design

authors： Frieden M,Ørum H

更新日期：2008-01-01 00:00:00

abstract：:Nonalcoholic fatty liver disease (NAFLD) affects about 20%-30% of the general population, and its clinical relevance arises from the fact that 20%-30% of these subjects develop non-alcoholic steatohepatitis (NASH), a condition at risk of cirrhosis progression. In addition NAFLD, and in particular NASH patients, are al...

journal_title：Current pharmaceutical design

authors： Petta S,Handberg A,Craxì A

更新日期：2013-01-01 00:00:00

abstract：:Pulmonary arterial hypertension (PAH) is a severe vascular complication of connective tissue diseases. In the context of systemic sclerosis (SSc), PAH is a devastating disease with a dramatic impact on prognosis and survival. Despite advances in early diagnosis and the development of new targeted treatments, SSc-relat...

journal_title：Current pharmaceutical design

authors： Dimitroulas T,Giannakoulas G,Karvounis H,Settas L,Kitas GD

更新日期：2012-01-01 00:00:00

abstract：:The drug discovery process in general is a very resource intensive undertaking that has existed for a very long time. In the last two decades, performing molecular simulations that determine the level of interaction between a protein and ligand have been refined to the point where they are now an essential part of the...

journal_title：Current pharmaceutical design

authors： Haga JH,Ichikawa K,Date S

更新日期：2016-01-01 00:00:00

abstract：:Diabetes is one of the most common endocrine non-communicable metabolic disorders which is mainly caused either due to insufficient insulin or inefficient insulin or both together and is characterized by hyperglycemia. Diabetes emerged as a serious health issue in the industrialized and developing country especially i...

journal_title：Current pharmaceutical design

authors： Prabhakar PK,Sivakumar PM

更新日期：2019-01-01 00:00:00

abstract：BACKGROUND:Clinic resting heart rate (RHR), is one of the cardiovascular parameters more easily measurable. In the general population RHR has been associated with total and cardiovascular mortality and higher rate of vascular events. OBJECTIVE:The case of essential hypertension is in some ways peculiar: in the past de...

journal_title：Current pharmaceutical design

authors： Di Raimondo D,Musiari G,Grova M,Miceli G,Tuttolomondo A,Pinto A

更新日期：2017-01-01 00:00:00

abstract：:This manuscript provides an overview for analysts, medical and scientific investigators, and laboratory administrators, the range of factors that should be considered to implement best practice forensic toxicology. These include laboratory influence over the collection of specimens, their proper transport and chain-of...

journal_title：Current pharmaceutical design

authors： Drummer OH

更新日期：2017-01-01 00:00:00

abstract：BACKGROUND:Familial Hypercholesterolaemia (FH) is an autosomal-dominant genetic disease and represents the most common genetic disorder: heterozygous 1/250 births, homozygous 1/300, 000 births. FH is characterized by high to very high low-density lipoprotein cholesterol (LDL-C), which is the main cause of increased inc...

journal_title：Current pharmaceutical design

authors： Viigimaa M,Heinsar S,Lovic D,Katsimardou A,Piperidou A,Duishvili D

更新日期：2018-01-01 00:00:00

abstract：:Inflammation is part of an important mechanism triggered by the innate immune response that rapidly responds to invading microorganisms and tissue injury. One important elicitor of the inflammatory response is the Gram-negative bacteria component lipopolysaccharide (LPS), which induces the activation of innate immune ...

journal_title：Current pharmaceutical design

authors： de Almeida OP Jr,Toledo TR,Rossi D,Rossetto Dde B,Watanabe TF,Galvão FC,Medeiros AI,Zanelli CF,Valentini SR

更新日期：2014-01-01 00:00:00

abstract：:Clopidogrel, in combination wih aspirin, is currently the drug of choice to prevent thrombosis after coronary stent implantation. Currently, clopidogrel is administered to the vast majority of patients without any assessment of platelet inhibition. Response variability and resistance, however, definitely occur to clop...

journal_title：Current pharmaceutical design

authors： Gurbel PA,Lau WC,Bliden KP,Tantry US

更新日期：2006-01-01 00:00:00

abstract：:Syncytin-1 is a protein coded by a human endogenous retrovirus (HERV) gene of the HERV-W family (HERVWE1). Syncytin- 1 mediates formation of syncytiotrophoblasts through fusion of cytotrophoblasts, a hallmark of terminal differentiation of placental trophoblast linage. Syncytin-1 also possesses nonfusogenic functions ...

journal_title：Current pharmaceutical design

authors： Zhuang XW,Li J,Brost BC,Xia XY,Chen HB,Wang CX,Jiang SW

更新日期：2014-01-01 00:00:00

abstract：:The number of protein 3D structures without function annotation in Protein Data Bank (PDB) has been steadily increased. Many of these proteins are relevant for Pharmaceutical Design because they may be enzymes of different classes that could become drug targets. This fact has led in turn to an increment of demand for ...

journal_title：Current pharmaceutical design

authors： Concu R,Podda G,Ubeira FM,González-Díaz H

更新日期：2010-01-01 00:00:00